UP TO 3,000 New Zealand post-menopausal women with early breast cancer will soon be able to have funded zoledronic acid, to prevent the disease spreading into bones, NZ's Pharmaceutical Management Agency (PHARMAC) has announced.
Zoledronic acid, an infusion that is given twice a year for two years, is already funded to treat osteoporosis and bone metastases in cancer patients, in both hospital and community settings.
The above article was sent to subscribers in Pharmacy Daily's issue from 15 Dec 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Dec 17
